TD Private Client Wealth’s Corcept Therapeutics CORT Stock Holding History

TD Private Client Wealth’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35K	Sell	27 -50	-65%	-$3.02K	﹤0.01%	1340
2026 Q1	$3.1K	Sell	77 -102	-57%	-$3.81K	﹤0.01%	1241
2025 Q4	$6.23K	Buy	179 +92	+106%	+$7.23K	﹤0.01%	1134
2025 Q3	$7.23K	Hold	87	–	–	﹤0.01%	1096
2025 Q2	$6.39K	Buy	+87	New	+$6.31K	﹤0.01%	1094
2023 Q1	–	Sell	-595	Closed	-$12.1K	–	1245
2022 Q4	$12.1K	Sell	595 -25	-4%	-$627	﹤0.01%	981
2022 Q3	$15.9K	Sell	620 -19	-3%	-$508	﹤0.01%	947
2022 Q2	$15.2K	Sell	639 -69	-10%	-$1.5K	﹤0.01%	955
2022 Q1	$15.9K	Buy	+708	New	+$15.1K	﹤0.01%	977

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Private Client Wealth's CORT Position: Q2 2026 in Review

TD Private Client Wealth reduced its Corcept Therapeutics (CORT) stake by 65% in Q2 2026, selling an estimated $3.02K and leaving 27 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

TD Private Client Wealth first reported a position in CORT in Q1 2022 and has held it in 9 quarters since. The position peaked at $15.9K in Q1 2022. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

TD Private Client Wealth held 27 shares of Corcept Therapeutics worth $2.35K as of Q2 2026.
TD Private Client Wealth sold 50 Corcept Therapeutics shares in Q2 2026, an estimated $3.02K.
Corcept Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1340 holding.
TD Private Client Wealth first reported a position in Corcept Therapeutics in Q1 2022 and has held it in 9 quarters since.
TD Private Client Wealth's Corcept Therapeutics position peaked at $15.9K in Q1 2022.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.